Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2026)
Caribou Biosciences (CRBU) reported Income from Continuing Operations of 26280000.0 for Q1 2026, up 38.76% year-over-year from 18939200.62 in Q1 2025, and up 7.64% on a QoQ basis from 28453000.0 in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of Income from Continuing Operations data on file, last reported at 26280000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 38.76% year-over-year to 26280000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 131711000.0 (up 19.46% YoY) and the FY2025 annual result came in at 148125000.0, up 0.66% from the prior year.
- Income from Continuing Operations rose to 26280000.0 in Q1 2026 per CRBU's latest filing, from 28453000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 14633000.0 in Q3 2023 and bottomed at 47578000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 31116000.0 (2023), against an average of 33158705.88.
- The widest annual swing landed in 2023, when Income from Continuing Operations soared 44.86%; it then plunged 161.31% in 2024.
- Tracing CRBU's Income from Continuing Operations over 5 years: stood at 30578000.0 in 2022, then retreated by 22.45% to 37442000.0 in 2023, then decreased by 3.83% to 38875000.0 in 2024, then rose by 26.81% to 28453000.0 in 2025, then climbed by 7.64% to 26280000.0 in 2026.
- Per Business Quant, the three latest CRBU Income from Continuing Operations figures stand at 26280000.0 (Q1 2026), 28453000.0 (Q4 2025), and 29400000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -26.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.28 Mn |
| Dec 31, 2025 | -28.45 Mn |
| Sep 30, 2025 | -29.40 Mn |
| Jun 30, 2025 | -47.58 Mn |
| Mar 31, 2025 | -42.91 Mn |
| Dec 31, 2024 | -38.88 Mn |
| Sep 30, 2024 | -38.24 Mn |
| Jun 30, 2024 | -43.50 Mn |
| Mar 31, 2024 | -46.00 Mn |
| Dec 31, 2023 | -37.44 Mn |
| Sep 30, 2023 | -14.63 Mn |
| Jun 30, 2023 | -32.87 Mn |
| Mar 31, 2023 | -31.12 Mn |
| Dec 31, 2022 | -30.58 Mn |
| Sep 30, 2022 | -26.54 Mn |
| Jun 30, 2022 | -28.43 Mn |
| Mar 31, 2022 | -20.85 Mn |
| Dec 31, 2021 | -18.48 Mn |
| Sep 30, 2021 | -20.97 Mn |
| Jun 30, 2021 | -14.31 Mn |
| Mar 31, 2021 | -13.16 Mn |
| Dec 31, 2020 | -14.70 Mn |
| Sep 30, 2020 | -7.93 Mn |
| Jun 30, 2020 | -1.87 Mn |
| Mar 31, 2020 | -9.80 Mn |